comparemela.com
Home
Live Updates
Health Canada Approves AbbVies RINVOQ® (upadacitinib) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA) : comparemela.com
Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at... | May 9, 2023
Related Keywords
Montreal
,
Quebec
,
Canada
,
Canadian
,
Canadians
,
Denis Choquette
,
Tracey Ramsay
,
Twitter
,
Canadian Spondylitis Association
,
Instagram
,
Canadian Spondyloarthritis Association
,
Health Canada
,
Abbvie Corporation
,
Linkedin
,
Janus Kinase
,
Institut De Rhumatologie
,
Scientific Director
,
Spondyloarthritis Association
,
Vice President
,
General Manager
,
Allergan Aesthetics
,
Ann Rheum
,
Understanding Axial Spondyloarthritis
,
Progression From Non Radiographic
,
Radiographic Axial Spondyloarthritis
,
Results From
,
Multicountry Prospective Observational
,
Ann Rheum Dis
,
Evaluate Efficacy
,
Adult Participants With Axial Spondyloarthritis
,
Canada Newswire
,
Abbvie Inc Stock Exchange
,
News
,
Information
,
Press Release
,
Approval
,
Us
,
Ased
,
N
,
Results
,
Rom
,
The
,
Hase
,
,
Pivotal
,
Linical
,
Trial
,
Which
,
Rinvoq
,
Elivered
,
Rapid
,
End
,
Meaningful
,
Disease
,
Meeting
,
Primary
,
Ndpoint
,
F
,
Sas40
,
Esponse Abbv Us00287y1091
,
comparemela.com © 2020. All Rights Reserved.